Rein Therapeutics
RNTX
40 hedge funds and large institutions have $9.76M invested in Rein Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
11% more funds holding
Funds holding: 36 → 40 (+4)
6.38% more ownership
Funds ownership: 30.05% → 36.43% (+6.4%)
2% more capital invested
Capital invested by funds: $9.54M → $9.76M (+$217K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$1.57M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$361K |
| 3 |
GS
Gagnon Securities
New York
|
+$199K |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$178K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$29.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$25.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$19.8K |
| 4 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
-$12.9K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$7.9K |
RNTX Hedge Fund Activity: Q3 2025 in Review
40 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2025, worth a combined $9.76M — up 2.3% from $9.54M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RNTX positions and 2 closed out — a net gain of 4 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Voss Capital, adding an estimated $1.57M. The largest seller was Sigma Planning Corp, cutting an estimated $29.1K.
- 40 institutional investors held Rein Therapeutics (RNTX) as of Q3 2025, up from 36 in Q2 2025.
- Funds reported $9.76M of Rein Therapeutics stock for Q3 2025, up 2.3% quarter-over-quarter.
- 6 funds opened new Rein Therapeutics positions in Q3 2025 and 2 closed out, a net change of +4 holders.
- The largest Rein Therapeutics buyer in Q3 2025 was Voss Capital, an estimated $1.57M added.
- The largest Rein Therapeutics seller in Q3 2025 was Sigma Planning Corp, an estimated $29.1K sold.
Based on aggregated 13F filings for Q3 2025.